Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma.

Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH, Carson WE 3rd.

J Surg Oncol. 2018 Sep;118(3):501-509. doi: 10.1002/jso.25163. Epub 2018 Aug 21.

PMID:
30132912
2.

Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.

Olaverria Salavaggione GN, Duggan MC, Carson WE.

Melanoma Res. 2018 Oct;28(5):390-397. doi: 10.1097/CMR.0000000000000474.

PMID:
30020196
3.

Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Santhanam R, Fang H, Dettorre GM, Gautam S, Harrington BK, Henderson SE, Merchand-Reyes G, Mo X, Benson DM, Carson WE 3rd, Vasu S, Byrd JC, Butchar JP, Tridandapani S.

Int Immunol. 2018 Jul 24;30(8):375-383. doi: 10.1093/intimm/dxy040.

PMID:
29868798
4.

Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.

Lai X, Stiff A, Duggan M, Wesolowski R, Carson WE 3rd, Friedman A.

Proc Natl Acad Sci U S A. 2018 May 22;115(21):5534-5539. doi: 10.1073/pnas.1721559115. Epub 2018 May 7.

PMID:
29735668
5.

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.

Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.

PMID:
29622581
6.

Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2018 Mar 6;8(1):4203. doi: 10.1038/s41598-018-21306-z.

7.

Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.

Suarez-Kelly LP, Akagi K, Reeser JW, Samorodnitsky E, Reeder M, Smith A, Roychowdhury S, Symer DE, Carson WE.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002352. doi: 10.1101/mcs.a002352. Print 2018 Apr.

8.

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, Landi I, Hsu V, Duggan M, Wesolowski R, Old M, Howard JH, Yu L, Stasik N, Olencki T, Muthusamy N, Tridandapani S, Byrd JC, Caligiuri M, Carson WE.

Clin Cancer Res. 2018 Apr 15;24(8):1891-1904. doi: 10.1158/1078-0432.CCR-17-0691. Epub 2018 Jan 23.

PMID:
29363526
9.

Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.

Xu J, Regan-Fendt K, Deng S, Carson WE, Payne PRO, Li F.

Pac Symp Biocomput. 2018;23:92-103.

10.

Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0. Erratum in: Sci Rep. 2018 Mar 6;8(1):4203.

11.

Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.

Duggan MC, Stiff AR, Bainazar M, Regan K, Olaverria Salavaggione GN, Maharry S, Blachly JS, Krischak M, Walker CJ, Latchana N, Tridandapani S, de la Chapelle A, Eisfeld AK, Carson WE 3rd.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9629-9634. doi: 10.1073/pnas.1704371114. Epub 2017 Aug 21.

12.

MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.

Campbell AR, Duggan MC, Suarez-Kelly LP, Bhave N, Opheim KS, McMichael EL, Trikha P, Parihar R, Luedke E, Lewis A, Yung B, Lee R, Raulet D, Tridandapani S, Groh V, Yu L, Yildiz V, Byrd JC, Caligiuri MA, Carson WE 3rd.

Cancer Immunol Res. 2017 Sep;5(9):778-789. doi: 10.1158/2326-6066.CIR-16-0005. Epub 2017 Jul 19.

13.

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

PMID:
28688082
14.

Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation.

Pyter LM, Suarez-Kelly LP, Carson WE 3rd, Kaur J, Bellisario J, Bever SR.

Behav Brain Res. 2017 Jul 14;330:108-117. doi: 10.1016/j.bbr.2017.05.011. Epub 2017 May 4.

15.

Plasma MicroRNA Levels Following Resection of Metastatic Melanoma.

Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE 3rd.

Bioinform Biol Insights. 2017 Feb 23;11:1177932217694837. doi: 10.1177/1177932217694837. eCollection 2017.

16.

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T.

J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.

PMID:
28463630
17.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

18.

Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.

Suarez-Kelly LP, Campbell AR, Rampersaud IV, Bumb A, Wang MS, Butchar JP, Tridandapani S, Yu L, Rampersaud AA, Carson WE 3rd.

Nanomedicine. 2017 Apr;13(3):909-920. doi: 10.1016/j.nano.2016.12.005. Epub 2016 Dec 18.

19.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

20.
21.

Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?

Alfano CM, Peng J, Andridge RR, Lindgren ME, Povoski SP, Lipari AM, Agnese DM, Farrar WB, Yee LD, Carson WE 3rd, Kiecolt-Glaser JK.

J Clin Oncol. 2017 Jan 10;35(2):149-156. Epub 2016 Nov 28.

22.

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE 3rd.

Oncotarget. 2016 Dec 6;7(49):81172-81186. doi: 10.18632/oncotarget.12791.

23.

Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S.

J Biol Chem. 2016 Dec 2;291(49):25656-25666. Epub 2016 Oct 25.

24.

MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches.

Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE 3rd.

Onco Targets Ther. 2016 Sep 29;9:5931-5941. eCollection 2016.

25.

Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors.

Latchana N, Regan K, Howard JH, Aldrink JH, Ranalli MA, Peters SB, Zhang X, Gru A, Payne PRO, Suarez-Kelly LP, Carson WE 3rd.

J Surg Res. 2016 Oct;205(2):350-358. doi: 10.1016/j.jss.2016.06.085. Epub 2016 Jul 4.

26.

MicroRNA dysregulation in melanoma.

Latchana N, Ganju A, Howard JH, Carson WE 3rd.

Surg Oncol. 2016 Sep;25(3):184-9. doi: 10.1016/j.suronc.2016.05.017. Epub 2016 May 20. Review.

PMID:
27566021
27.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.

PMID:
27496110
28.

Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling.

Latchana N, Del Campo SE, Grignol VP, Clark JR, Albert SP, Zhang J, Wei L, Aldrink JH, Nicol KK, Ranalli MA, Peters SB, Gru A, Trihka P, Payne PR, Howard JH, Carson WE 3rd.

Ann Surg Oncol. 2017 Feb;24(2):347-354. doi: 10.1245/s10434-016-5476-9. Epub 2016 Jul 28.

PMID:
27469124
29.

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.

Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson GA.

Mol Cancer Ther. 2016 Sep;15(9):2244-50. doi: 10.1158/1535-7163.MCT-15-0879. Epub 2016 Jul 25.

30.

IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, Tridandapani S, Bloomston M, Ellison EC, Williams TM, Bekaii-Saab T, Carson WE 3rd.

Clin Cancer Res. 2017 Jan 15;23(2):489-502. doi: 10.1158/1078-0432.CCR-16-0004. Epub 2016 Jul 19.

31.

Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years.

Andersen BL, Goyal NG, Westbrook TD, Bishop B, Carson WE 3rd.

Clin Cancer Res. 2017 Jan 1;23(1):52-61. doi: 10.1158/1078-0432.CCR-16-0574. Epub 2016 Jul 12.

32.

A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.

Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE 3rd, Basu S, Bai XF.

J Immunol. 2016 Aug 15;197(4):1489-97. doi: 10.4049/jimmunol.1600052. Epub 2016 Jul 6.

33.

NKp80 Defines a Critical Step during Human Natural Killer Cell Development.

Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE 3rd, Caligiuri MA.

Cell Rep. 2016 Jul 12;16(2):379-391. doi: 10.1016/j.celrep.2016.05.095. Epub 2016 Jun 30.

34.

A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets.

Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, Mao HC, McClory S, Yu J, Carson WE 3rd, Caligiuri MA, Freud AG.

Immunity. 2016 May 17;44(5):1140-50. doi: 10.1016/j.immuni.2016.04.007. Epub 2016 May 10.

35.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Apr;14(4):450-73.

PMID:
27059193
36.

Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.

Skinner CC, McMichael EL, Jaime-Ramirez AC, Abrams ZB, Lee RJ, Carson WE 3rd.

Melanoma Res. 2016 Aug;26(4):329-37. doi: 10.1097/CMR.0000000000000258.

37.

Structural characterization of NRAS isoform 5.

Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE 3rd.

Protein Sci. 2016 May;25(5):1069-74. doi: 10.1002/pro.2916. Epub 2016 Mar 24.

38.

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd.

Cancer Res. 2016 Apr 15;76(8):2125-36. doi: 10.1158/0008-5472.CAN-15-1490. Epub 2016 Feb 15.

39.

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd.

Cancer Immunol Res. 2016 Apr;4(4):323-336. doi: 10.1158/2326-6066.CIR-15-0168. Epub 2016 Feb 10.

40.

A Comprehensive Program for the Enhancement of Accrual to Clinical Trials.

Porter M, Ramaswamy B, Beisler K, Neki P, Single N, Thomas J, Hofacker J, Caligiuri M, Carson WE 3rd.

Ann Surg Oncol. 2016 Jul;23(7):2146-52. doi: 10.1245/s10434-016-5091-9. Epub 2016 Jan 20.

PMID:
26790668
41.

Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.

Grignol VP, Smith AD, Shlapak D, Zhang X, Del Campo SM, Carson WE.

Surg Oncol. 2015 Dec;24(4):353-8. doi: 10.1016/j.suronc.2015.09.002. Epub 2015 Oct 22.

PMID:
26690825
42.

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE 3rd, Butchar JP, Tridandapani S.

J Biol Chem. 2016 Feb 5;291(6):3043-52. doi: 10.1074/jbc.M115.687251. Epub 2015 Dec 1.

43.

MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.

Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, Walker CJ, Markowitz J, Carson WE 3rd, Eisfeld AK, de la Chapelle A.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):E6744-51. doi: 10.1073/pnas.1520390112. Epub 2015 Nov 18.

44.

ASCO 2015 update on melanoma.

Carson WE 3rd.

Surg Oncol. 2015 Dec;24(4):363-5. doi: 10.1016/j.suronc.2015.10.005. Epub 2015 Oct 26. No abstract available.

PMID:
26564261
45.

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM.

J Natl Compr Canc Netw. 2015 Nov;13(11):1337-46.

PMID:
26553764
46.

Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.

Campbell AR, Regan K, Bhave N, Pattanayak A, Parihar R, Stiff AR, Trikha P, Scoville SD, Liyanarachchi S, Kondadasula SV, Lele O, Davuluri R, Payne PR, Carson WE 3rd.

BMC Med Genomics. 2015 Oct 15;8:66. doi: 10.1186/s12920-015-0142-9.

47.

Surgical management of ovarian carcinoma metastatic to the breast and axilla: A role for metastasectomy?

Rossfeld KK, Carson WE 3rd.

J Surg Oncol. 2015 Nov;112(6):581-4. doi: 10.1002/jso.24055. Epub 2015 Oct 13.

PMID:
26459120
48.

Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.

Shu D, Li H, Shu Y, Xiong G, Carson WE 3rd, Haque F, Xu R, Guo P.

ACS Nano. 2015 Oct 27;9(10):9731-40. doi: 10.1021/acsnano.5b02471. Epub 2015 Sep 21.

49.

Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.

Smith AD, Gray MR, del Campo SM, Shlapak D, Ganeshan B, Zhang X, Carson WE 3rd.

AJR Am J Roentgenol. 2015 Sep;205(3):W283-93. doi: 10.2214/AJR.15.14315.

PMID:
26295664
50.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

Supplemental Content

Loading ...
Support Center